Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

NCT ID: NCT06024421

Last Updated: 2024-05-20

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-14
• Study Completion Date: 2027-11-30

Brief Summary

FAVIDOSE trial is a Phase I randomized, double blind controlled, monocentric, dose escalation clinical trial. The primary purpose of this trial is to evaluate tolerance of high doses of favipiravir for 14 days in healthy volunteers. This trial also looks to characterize favipiravir pharmacokinetics in blood and favipiravir levels in sperm. A pharmacogenetics analysis will be conducted in an attempt to identify genetic variants of metabolism and transport enzymes of favipiravir to explain the inter-individual variability of pharmacokinetic parameters of favipiravir.

Three sequential dose levels including distinctive participants:

• level 1: D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning;
• level 2: D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning;
• level 3: D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning.

Three study groups of maximum of 8 participants, 6 receiving favipiravir and 2 receiving placebo per dose level, three dose levels proposed. Seven additional participants with the same follow up will be included and randomized (6:1 ratio) at the maximum tolerated dose level to allow a satisfactory accurate characterization of pharmacokinetics and pharmacogenetics of favipiravir and their determinants (maximum 39 participants in total, taking into account 8 participants - 2 per dose level - replaced because loss of follow-up before the end of treatment).

Conditions

Infectious Disease; Pharmacology

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

level 1: experimental

D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning

Group Type: EXPERIMENTAL

favipiravir

Intervention Type: DRUG

Light yellow, film-coated tablet, each containing 200 mg of favipiravir

level 2: experimental

D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning

Group Type: EXPERIMENTAL

favipiravir

Intervention Type: DRUG

Light yellow, film-coated tablet, each containing 200 mg of favipiravir

level 3: experimental

D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning

Group Type: EXPERIMENTAL

favipiravir

Intervention Type: DRUG

Light yellow, film-coated tablet, each containing 200 mg of favipiravir

level 1: placebo

D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Light yellow, film-coated tablet

level 2: placebo

D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Light yellow, film-coated tablet

level 3: placebo

D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Light yellow, film-coated tablet

Interventions

favipiravir

Light yellow, film-coated tablet, each containing 200 mg of favipiravir

Intervention Type: DRUG

Placebo

Light yellow, film-coated tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Man between 50 and 75 years old without any desire to have children or woman between 18 and 75 years old ;

2. Subject considered healthy after a thorough general examination (questioning, physical examination);

3. For men: acceptance of semen collection by masturbation;

4. For men: acceptance of condom use from initiation of the investigational drug until 1 month after stopping the investigational drug;

5. For women of childbearing potential: effective contraceptive method combining two methods of contraception (one female contraceptive method combined with male condom use) from the inclusion visit until 1 month after discontinuation of the investigational drug;

6. Blood chemistry:

• Kalemia, Calcemia, Prothrombin rate (PT), Activated partial thromboplastin time (APTT): values within laboratory normal;
• ALT, ASAT, Uricemia: values below the upper limit of the laboratory normal;
• Other biological results (Blood count; Natremia; Phosphoremia; Chloremia; Fasting blood glucose; Gamma glutamyl transpeptidase; Urea; Total bilirubin; Creatinine; CPK; Lactate dehydrogenase; Albuminemia; Proteinemia; Triglycerides; C-reactive protein; Albumin/Globulin ratio; Alkaline phosphatase) with no clinically significant abnormality.

NB: A parameter outside the usual values considered clinically significant may, at the investigator's discretion, be tested a second time on another sample taken outside of a visit planned in the protocol before the initiation of the experimental drug.

7. Urine dipstick (biochemistry: leukocyturia, proteinuria and hematuria) without clinically significant abnormality;

8. Urine tox screen negative (amphetamines/metamphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates);

9. Ability to take the investigational drug orally and adherence to the dosage of the investigational drug;

10. Acceptance and signing of the informed consent;

11. Membership in a social security plan or beneficiary of such a plan;

12. Adherence to lifestyle considerations (see section 5.5) during participation in this research.

Exclusion Criteria

1. Concomitant use or within 15 days prior to inclusion of another QT/QTc prolonging drug or drugs that may disrupt electrolyte levels, among others: loop diuretics, thiazide diuretics and related drugs (see list www.crediblemeds.org)

2. History of amiodarone use within 6 months prior to inclusion

3. History of gout or current treatment for gout or hyperuricemia

4. Treatment with pyrazinamide or any other drug known to induce hyperuricemia

5. History of hypersensitivity reaction to a nucleoside analog targeting viral RNA polymerase

6. Known hypersensitivity to any of the components (favipiravir or placebo)

7. Pregnant or breastfeeding women

8. For men: history of vasectomy or known history of infertility.

9. Refusal of the subject to complete all the visits, clinical and paraclinical examinations planned by the study

10. On ECG: PR >200ms, QRS >100ms QTc >450ms and morphological appearance of abnormal repolarization

11. PAS <100 mmHg

12. Any history or active cardiovascular, pulmonary, intestinal, hepatic, renal, metabolic, hematologic, neurologic, bone, joint, muscular, psychiatric, systemic, ocular, gynecologic, andrologic, or infectious disease (including active HIV, HCV, or HBV infection), or any acute condition, which in the judgment of the investigator could be detrimental to the volunteer and/or interfere with or limit the protocol evaluation and data analysis

13. Personal or family history of long QT syndrome, torsades de pointes or sudden death

14. Patient with severe hepatic impairment

15. Gastrointestinal pathology such as ileus, colitis or enterocolitis

16. Treatment with another investigational drug or other investigational procedure (clinical trial, clinical investigation of a medical device, category 1 or 2 research involving humans);

17. A person who is subject to a legal protection measure (safeguard of justice, curatorship, guardianship);

18. Person placed in administrative detention;

19. Person who, in the judgment of the investigating physician, may be non-observant during the study, or unable to communicate due to a language barrier or mental disorder

20. Person who cannot be contacted in an emergency

21. Person with at least one first-degree relative from East Asia or Southeast Asia.

Participants with at least one of the following criteria will not start the experimental treatment at D1 if they are already randomized:

1. Positive nasopharyngeal antigen test for SARS-CoV-2 at D1 (prior to treatment initiation)

2. Blood potassium levels outside the normal laboratory range within 8 days prior to treatment initiation (D1)

3. ECG: PR >200ms, QRS >100ms QTc >450ms and morphological appearance of abnormal repolarization on Day 1

4. Positive pregnancy test on Day 1 (before initiation of treatment)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

FUJIFILM Toyama Chemical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Denis MALVY

Role: STUDY_CHAIR

CHU de Bordeaux & INSERM, Université de Bordeaux, France

Xavier DUVAL

Role: PRINCIPAL_INVESTIGATOR

APHP Hôpital Bichat Claude Bernard

Helene ESPEROU

Role: STUDY_DIRECTOR

Institut National de la Santé Et de la Recherche Médicale, France

Locations

University Hospital Bichat - Claude Bernard

Paris, , France

Site Status: RECRUITING

Countries

France

Central Contacts

France MENTRE

Role: CONTACT

france.mentre@inserm.fr

+33 1 40 25 79 31

Cedric LAOUNAN

Role: CONTACT

cedric.laouenan@inserm.fr

+33 1 40 25 79 31

Facility Contacts

Xavier Duval

Role: primary

Other Identifiers

2022-502871-49-00

Identifier Type: OTHER

Identifier Source: secondary_id

C18-47

Identifier Type: -

Identifier Source: org_study_id